Astria Therapeutics

9 Meters Biopharma (NASDAQ: NMTR) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$0.78 0.03 4.00
Volume: 42,537
5-Day Change: 11.43%
YTD Change: -38.10%
Market Cap: US$11.280M

Latest News From 9 Meters Biopharma

May 30, 2023
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately. Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf... Read More
May 15, 2023
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential... Read More
April 5, 2023
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment... Read More
March 28, 2023
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022. "Our priority for 2023 remains to progress our Phase 3 vurolenatide... Read More
March 15, 2023
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined... Read More
March 14, 2023
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of... Read More
March 7, 2023
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33 rd Annual Healthcare Conference. Oppenheimer 33 rd Annual Healthcare Conference Date: Monday, March... Read More
January 31, 2023
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City. The... Read More
November 29, 2022
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependence Study design allows for the assessment of the entirety of the short bowel syndrome patient population US IRB approval secured; study to include up to 50 sites in North America and Europe and remains on track with study initiation as early as end-of-year RALEIGH, NC /... Read More
ClearPoint Neuro

COPYRIGHT ©2023 HEALTH STOCKS HUB